Point72 (DIFC)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$31.6K Sell
700
-15,000
-96% -$701K ﹤0.01% 804
2025
Q2
$727K Sell
15,700
-2,100
-12% -$103K 0.03% 479
2025
Q1
$1.09M Sell
17,800
-135,200
-88% -$7.88M 0.04% 449
2024
Q4
$8.65M Sell
153,000
-293,200
-66% -$16.4M 0.32% 70
2024
Q3
$23.1M Buy
446,200
+351,600
+372% +$16.5M 0.78% 20
2024
Q2
$3.93M Buy
94,600
+50,000
+112% +$2.24M 0.14% 198
2024
Q1
$2.42M Buy
+44,600
New +$2.27M 0.08% 349

Other funds holding BMY

Point72 (DIFC)'s BMY Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Bristol-Myers Squibb (BMY) in Q3 2025: 107,251 shares worth $4.84M. The stake represents 0.32% of the portfolio and ranks #80 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in BMY as recently as Q4 2024.

Point72 (DIFC) first reported a position in BMY in Q2 2024 and has held it in 3 quarters since. The position peaked at $26.6M in Q2 2024. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

  • Point72 (DIFC) held 107,251 shares of Bristol-Myers Squibb worth $4.84M as of Q3 2025.
  • Bristol-Myers Squibb was a new Point72 (DIFC) position in Q3 2025.
  • Bristol-Myers Squibb made up 0.32% of Point72 (DIFC)'s portfolio in Q3 2025, its #80 holding.
  • Point72 (DIFC) first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s Bristol-Myers Squibb position peaked at $26.6M in Q2 2024.
  • 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.